Checkmate: kidney injury associated with targeted cancer immunotherapy

Mark A Perazella

doi:10.1016/j.kint.2016.05.024

Checkmate: kidney injury associated with targeted cancer immunotherapy

Kidney Int. 2016 Sep;90(3):474-6. doi: 10.1016/j.kint.2016.05.024.

Author

Mark A Perazella¹

Affiliation

¹ Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Section of Nephrology, Department of Medicine, VA Medical Center, West Haven, Connecticut, USA. Electronic address: Mark.perazella@yale.edu.

PMID: 27521108
DOI: 10.1016/j.kint.2016.05.024

Abstract

Immune checkpoint inhibitors are a class of drugs that utilizes immunotherapy to target various cancers. Included are the anti-CTLA-4 and anti-PD-1 receptor antibodies. By reprogramming the immune system, these agents provide a therapy that destroys cancer cells. However, this approach runs the risk of allowing pathologic autoimmunity and organ injury to develop. Unsurprisingly, immune-related adverse effects are described including pneumonitis, colitis, and various endocrinopathies. Now added to this list is AKI, primarily due to ATIN.

MeSH terms

Cell Cycle Checkpoints / immunology
Drug-Related Side Effects and Adverse Reactions
Humans
Immunotherapy*
Neoplasms
Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

Programmed Cell Death 1 Receptor